Key result
Declining lipoprotein lipase (LPL) levels were causally associated with an elevated risk of lung adenocarcinoma, and elevated LPL levels were positively associated with improved survival.
Why the study?
Lung adenocarcinoma is a leading cause of death worldwide, necessitating the exploration of more biomarkers and therapeutic targets.
Does lipoprotein lipase (LPL) act as a diagnostic and prognostic marker for lung adenocarcinoma?
Does lipoprotein lipase (LPL) act as a diagnostic and prognostic marker for lung adenocarcinoma?
LPL is identified as a potential diagnostic and prognostic biomarker for lung adenocarcinoma, with its activation inhibiting cancer cell proliferation and migration.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for lipoprotein lipase in LUAD; requires prospective validation before clinical translation.
Lung adenocarcinoma (LUAD) is one of the leading causes of death worldwide, and thus, more biomarker and therapeutic targets need to be explored. Herein, we aimed to explore new biomarkers of LUAD by integrating bioinformatics analysis with cell experiments. We firstly identified 266 druggable genes that were significantly differentially expressed between LUAD tissues and adjacent normal lung tissues. Among these genes, SMR analysis with p-value correction suggested that declining lipoprotein lipase (LPL) levels may be causally associated with an elevated risk of LUAD, which was corroborated by co-localization analysis. Analyses of clinical data showed that LPL in lung cancer tissues has considerable diagnostic value for LUAD, and elevated LPL levels were positively associated with improved patient survival outcomes. Cell experiments with an LPL activator proved these findings; the activator inhibited the proliferation and migration of lung cancer cells. Next, we found that LPL promoted the infiltration of immune cells such as DCs, IDCs, and macrophages in LUAD by mononuclear sequencing analysis and TIMER2.0. Meanwhile, patients with low levels of LPL expression demonstrated superior immunotherapeutic responses to anti-PD-1 therapy. We conclude that LPL acts as a diagnostic and prognostic marker for LUAD.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied Lung adenocarcinoma. Lipoprotein lipase (LPL) levels was evaluated on Risk of lung adenocarcinoma and patient survival outcomes. Declining lipoprotein lipase (LPL) levels were causally associated with an elevated risk of lung adenocarcinoma, and elevated LPL levels were positively associated with improved survival.
Synapse has enriched 10 related papers. Consider them for comparative context: